Puriblood Medical Co., Ltd. (TPEX:6847)

Market Cap	1.06B -4.9%
Revenue (ttm)	82.34M -25.6%
Net Income	-39.00M
EPS	-2.74
Shares Out	14.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,261
Open	74.40
Previous Close	74.50
Day's Range	71.10 - 74.50
52-Week Range	47.75 - 93.70
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Puriblood Medical

Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan and internationally. The company offers leukoreduction, cell separation, and P-Tex, an anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2015
• Employees: 38
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6847

Financial Performance

In 2025, Puriblood Medical's revenue was 82.34 million, a decrease of -25.61% compared to the previous year's 110.67 million. Losses were -39.00 million, 626.7% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 21, 2026

Data Sources Report a data error